| scholarly article | Q13442814 |
| P356 | DOI | 10.1158/1078-0432.CCR-16-2411 |
| P698 | PubMed publication ID | 28373362 |
| P50 | author | Andrew Biankin | Q38802580 |
| Peter J Bailey | Q56840335 | ||
| Stephan Dreyer | Q84923237 | ||
| P2093 | author name string | David K Chang | |
| P2860 | cites work | Core signaling pathways in human pancreatic cancers revealed by global genomic analyses | Q24606006 |
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pancreatic cancer | Q212961 |
| P304 | page(s) | 1638-1646 | |
| P577 | publication date | 2017-04-01 | |
| P1433 | published in | Clinical Cancer Research | Q332253 |
| P1476 | title | Pancreatic Cancer Genomes: Implications for Clinical Management and Therapeutic Development | |
| P478 | volume | 23 |
| Q89665129 | A novel derivative of valepotriate inhibits the PI3K/AKT pathway and causes Noxa-dependent apoptosis in human pancreatic cancer cells |
| Q47735303 | Advances in Molecular Profiling and Categorisation of Pancreatic Adenocarcinoma and the Implications for Therapy. |
| Q96817977 | Can computational modeling help in personalizing the care of patients with pancreatic ductal adenocarcinoma? |
| Q91949969 | Chemotherapy, host response and molecular dynamics in periampullary cancer: the CHAMP study |
| Q49630827 | Early stage pancreatic cancer |
| Q92810154 | Establishment and Characterization of Paired Primary Cultures of Human Pancreatic Cancer Cells and Stellate Cells Derived from the Same Tumor |
| Q91199443 | From state-of-the-art treatments to novel therapies for advanced-stage pancreatic cancer |
| Q47232401 | Genomics-Driven Precision Medicine for Advanced Pancreatic Cancer - Early Results from the COMPASS Trial. |
| Q88963818 | Immunotherapy and Prevention of Pancreatic Cancer |
| Q91611860 | Inflammation, Biomarkers and Immuno-Oncology Pathways in Pancreatic Cancer |
| Q91789132 | Is there a CDKN2A-centric network in pancreatic ductal adenocarcinoma? |
| Q92978701 | Machine Learning and Network Analyses Reveal Disease Subtypes of Pancreatic Cancer and their Molecular Characteristics |
| Q58588518 | MiR-216b inhibits pancreatic cancer cell progression and promotes apoptosis by down-regulating |
| Q91341271 | Molecular subtypes of pancreatic cancer |
| Q47979409 | New Developments in the Molecular Mechanisms of Pancreatic Tumorigenesis. |
| Q93167473 | Oncolytic Virus-Mediated Targeting of the ERK Signaling Pathway Inhibits Invasive Propensity in Human Pancreatic Cancer |
| Q55104265 | Pancreatic Cancer: Molecular Characterization, Clonal Evolution and Cancer Stem Cells. |
| Q89584288 | Phase Ib trial combining capecitabine, erlotinib and bevacizumab in pancreatic adenocarcinoma - REBECA trial |
| Q90663504 | Precision Oncology in Surgery: Patient Selection for Operable Pancreatic Cancer |
| Q41637362 | Re-engineering the Pancreas Tumor Microenvironment: A "Regenerative Program" Hacked |
| Q90149903 | Recent advances in the treatment of pancreatic cancer |
| Q58711248 | SERPINB7 Expression Predicts Poor Pancreatic Cancer Survival Upon Gemcitabine Treatment |
| Q52691832 | Strategies for Increasing Pancreatic Tumor Immunogenicity. |
| Q54976514 | The ATR inhibitor AZD6738 synergizes with gemcitabine in vitro and in vivo to induce pancreatic ductal adenocarcinoma regression. |
| Q91925397 | The reciprocal regulation between host tissue and immune cells in pancreatic ductal adenocarcinoma: new insights and therapeutic implications |
| Q52654643 | Upper gastrointestinal malignancies in 2017: current perspectives and future approaches. |
| Q93077995 | Wnt/β-Catenin Signaling: The Culprit in Pancreatic Carcinogenesis and Therapeutic Resistance |
| Q58561906 | [Personalized cancer medicine : Biomarkers for molecular therapy stratification in pancreatic carcinoma] |
Search more.